Document text
Principal Investigator: Aleksandra Nita-Lazar
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $2,762
Funding agency: National Institute of Allergy and Infectious Diseases
The focus of the proteomic approach is to identify and quantify viral structural proteins, specifically spike (S) glycoprotein as well as envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein in patient samples. The S protein mediates attachment of the virus to the host cell surface receptors and subsequent fusion of the viral and host cell membranes to facilitate viral entry into the host cell. The S1 subunit of the ectodomain mediates binding of the virion to host cell-surface receptors through its receptor-binding domain and is the immunodominant epitope.
Due to its critical role in cell entry, we anticipate high expression levels of the S protein during active infection making it an attractive diagnostic marker for SARS-CoV-2 infection. Additionally, levels of this protein are expected to change during the course of infection and can be used to monitor individual disease progression. Finally, our proposed proteomic based detection of the S protein could prove helpful in studies evaluating the efficacy of novel drugs and vaccines in the light of the most current research (1).
Specific goals:
1) Development of proteomic based assay for detection and quantitation of SARS-CoV-2 proteome in biological samples. Work will focus on four structural proteins: spike (S) glycoprotein (primary target), envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. The E and N gene (coding for the envelop and nucleocapsid protein) have been used for PCR based diagnostic assays. We therefore aim to explore using their encoded products as additional targets in our proteomics assay development.
2) Characterize and compare SARS-CoV-2 protein profiles among patients, treatments (currently: a clinical study of fostamatinib as a possible therapeutic in addition to Remdesivir), different times of the course of disease and possible co-morbidities (such as RSV) using nasopharyngeal and respiratory samples from patients admitted at the NIH previously tested with N1, N2 RT-PCR CDC RT-PCR assay and using genomic data from the research proposal Genomics of SARS-CoV-2
3) Comparison of protein profiles and correlation with RNA detection assays. This will provide protein level information regarding observed differences between N1 and N2 levels among patients as observed by RT-PCR assay.
4) Selection of viral proteomic biomarker(s) for further evaluation as diagnostic and prognostic target in different clinical samples (saliva, urine, serum)
Bibliography:
1. Buszko M, Nita-Lazar A, Park JH, Schwartzberg PL, Verthelyi D, Young HA, Rosenberg AS. Nat Immunol. 2021 Apr;22(4):404-411.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Accounting><Assay><Bibliography><Binding><Bioassay><Biologic Assays><Biological><Biological Assay><Biological Markers><Blood Serum><CDC><COVID-19><COVID-19 diagnosis><COVID-19 infection><COVID-19 virus><COVID19><COVID19 diagnosis><COVID19 infection><COVID19 virus><CV-19><CV19><Cell Body><Cell Surface Receptors><Cell membrane><Cells><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><Clinical><Clinical Research><Clinical Study><CoV emergence><CoV-2><CoV2><Code><Coding System><Coronaviridae><Coronavirus><Cytoplasmic Membrane><Death><Detection><Development><Diagnosis><Diagnostic><Disease><Disease Progression><Disorder><Envelope Protein><Evaluation><GS-5734><Genes><Genomics><Glycoproteins><Goals><Human><Immunodominant Antigenic Determinants><Immunodominant Determinants><Immunodominant Domains><Immunodominant Epitopes><Immunodominant Regions><Immunodominant Sites><Individual><Infection><Maps><Mediating><Membrane><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Modern Man><Molecular Interaction><Monitor><NIH><National Institutes of Health><Non-Polyadenylated RNA><Nucleocapsid><Nucleocapsid Proteins><Patients><Plasma Membrane><Proteins><Proteome><Proteomics><RNA><RNA Gene Products><RT-PCR><RTPCR><Research><Research Proposals><Reverse Transcriptase Polymerase Chain Reaction><Ribonucleic Acid><Risk><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 diagnosis><SARS-CoV-2 infection><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Saliva><Sampling><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Sputum><Structural Protein><Surface Proteins><Testing><Therapeutic><Time><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Urine><Urine Urinary System><Veklury><Viral><Viral Structural Proteins><Virion><Virus><Virus Particle><Work><Wuhan coronavirus><assay development><base><bio-markers><biologic marker><biomarker><biomarker discovery><co-morbid><co-morbidity><comorbidity><comparative><corona virus><corona virus disease 2019><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 diagnosis><coronavirus disease 2019 infection><coronavirus disease 2019 virus><coronavirus emergence><detection assay><developmental><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><diagnostic assay><diagnostic biomarker><diagnostic marker><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><env Antigens><env Gene Products><env Polyproteins><env Protein><evaluate efficacy><examine efficacy><genomic data><genomic data-set><genomic dataset><hCoV19><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><membrane structure><nCoV><nCoV2><new CoV><new corona virus><new coronavirus><new drug treatments><new drugs><new therapeutics><new therapy><new vaccines><next generation therapeutics><next generation vaccines><novel CoV><novel corona virus><novel coronavirus><novel drug treatments><novel drugs><novel therapeutics><novel therapy><novel vaccines><plasmalemma><prognostic><receptor binding><receptor bound><remdesivir><respiratory><response to treatment><reverse transcriptase PCR><severe acute respiratory syndrome coronavirus 2 diagnosis><social role><therapeutic response><treatment response>